161Tb-NYM032

N/A

Report date: 2025/11/20 11:37:52
NME

Base Information

Drug Name161Tb-NYM032
Drug Alias Name161Tb-NYM032
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Terbium > 161TbRadiation-emitting products > Radionuclide Drug Conjugates +[4
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsPositron-emission tomography enhancers
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A